LIR Life Sciences Corp.

LIR Life Sciences Corp.

0.10
EUR
-0.01
(-10.91%)
-0.08EPS
10.21MMarket Cap

Total Valuation

EUR

As of April 30, 2026, LIR Life Sciences Corp. carries a market capitalization of 10.21M, placing it among publicly traded companies globally. Its enterprise value stands at 9.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.21M
Enterprise Value9.83M

Share Statistics

As of April 30, 2026, LIR Life Sciences Corp. has 28.67M shares outstanding.

Shares Outstanding28.67M

Valuation Ratios

These figures are as of April 30, 2026.

PB Ratio24.79
P/TBV Ratio24.79
P/FCF Ratio-7.40
P/OCF Ratio-7.78

Financial Position

As of April 30, 2026, LIR Life Sciences Corp. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Current Ratio4.64
Quick Ratio3.68
Interest Coverage-5,652.31

Financial Efficiency

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -786.68, reflecting losses generated across the asset base.

Return on Assets (ROA)-786.68

Stock Price Statistics

EUR

As of the close on October 22, 2026, LIR Life Sciences Corp.'s stock has declined approximately 43.19% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.38.

52-Week Price Change-43.19%
50-Day Moving Average0.13
200-Day Moving Average0.38

Income Statement

EUR

Over the twelve months ended April 30, 2026, LIR Life Sciences Corp. generated - - in revenue and converted that into -2.36M in net income, yielding earnings per share of -0.08. EBITDA reached -2.13M, while operating income came in at -2.09M.

Operating Income-2.09M
Pretax Income-2.36M
Net Income-2.36M
EBITDA-2.13M
EBIT-2.13M
Earnings Per Share (EPS)-0.08

Balance Sheet

EUR

These figures are as of April 30, 2026. Total book value stands at 411,667.76, with working capital of 411,667.76 providing operational flexibility.

Cash & Cash Equivalents374,204.25
Net Debt-374,204.25
Equity (Book Value)411,667.76
Book Value Per Share0.01
Working Capital411,667.76

Cash Flow

EUR

LIR Life Sciences Corp. produced -1.28M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -65,856.41 in capital expenditures, free cash flow totaled -1.35M - equivalent to -0.05 per share.

Operating Cash Flow-1.28M
Capital Expenditures-65,856.41
Free Cash Flow-1.35M
FCF Per Share-0.05

Dividends & Yields

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -13.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

FCF Yield-13.51

Stock Splits

LIR Life Sciences Corp.'s most recent stock split took place on November 7, 2025 with a 3:2 split ratio.

Last Split Date11/7/2025
Split Ratio3:2

Scores

As of April 30, 2026, LIR Life Sciences Corp. has an Altman Z-Score of 34.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score34.64